Amgen Inc

Get AIMOVIG delivered to your door with fast shipping nationwide.

Never wait in line at the pharmacy again.

Patients pay as little as $0 out-of-pocket for AIMOVIG.
Amgen Inc will pay the remaining co-payment or cost-sharing obligation per fill.

Once your prescription is transferred, it is shipped in 1-2 days.

Manufacturer Promotional Price



Want FREE shipping? Ask us how to qualify

Select Medication

* Valid prescription required. Patient must meet all eligibility
requirements to apply discount coupon.

Why migraine patients love Truepill

Easy Rx Transfer

A licensed pharmacist will review your information online and transfer your medication automatically.

Fast Shipping

No need to wait in line at a pharmacy. Your FDA-approved medications are delivered straight to your door.

Ongoing Support

Message a pharmacist anytime online for support with your treatment, and get refills delivered automatically.

What people are saying about AIMOVIG

Talk to a member
of our team

If you have any questions please contact our care team at (650) 353-5495 or

We accept your insurance

We accept a wide range of insurance providers. If you have any coverage questions give us a call at (650) 399-9905 or go through the order process and enter your insurance. We will contact you to let you know your copay pricing.


We offer two categories of migraine medications - medications for immediate relief and preventative medications. Your doctor will design a treatment plan tailored to your situation, to reduce the number of migraines you experience each month. Learn more about migraine medications
The initial doctor consult is $20 with or without insurance. For medications, we accept all major insurance plans. Your insurance copays are dependant on your insurance provider. We will run your insurance claim and notify you of your copay before shipping your medications.
Yes, you can purchase the medications your doctor prescribes as part of your treatment plan at our cash price.
We accept all major insurance providers and can run your insurance to tell you what your copay will be. Your copays will always be the exact same as what you pay at your current pharmacy.

We will ask you during your order completion process if you want to use insurance or cash. If you select insurance you can provide your insurance details and we will notify you of your copay pricing. We will also always compare your copay pricing with the cash price of the drug and give you full control to choose how you want to pay for your medication.
Truepill is a licensed U.S. pharmacy and ships to all 50 states and Washington DC. We currently do not ship to Puerto Rico and other U.S. territories.


11 DESCRIPTION Erenumab-aooe is a human immunoglobulin G2 (IgG2) monoclonal antibody that has high affinity binding to the calcitonin gene-related peptide receptor. Erenumab-aooe is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. It is composed of 2 heavy chains, each containing 456 amino acids, and 2 light chains of the lambda subclass, each containing 216 amino acids, with an approximate molecular weight of 150 kDa. AIMOVIG (erenumab-aooe) injection is supplied as a sterile, preservative-free, clear to opalescent, colorless to light yellow solution for subcutaneous administration. Each 1 mL single-dose prefilled autoinjector and single-dose prefilled glass syringe contains 70 mg erenumab-aooe, acetate (1.5 mg), polysorbate 80 (0.10 mg), and sucrose (73 mg). Enclosed within the autoinjector is a single-dose, prefilled glass syringe. The solution of AIMOVIG has a pH of 5.2.
6 ADVERSE REACTIONS The most common adverse reactions in AIMOVIG clinical studies (occurring in at least 3% of treated patients and more often than placebo) are injection site reactions and constipation (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Amgen Medical Information at 1-800-77-AMGEN (1-800-772-6436) or FDA at 1-800-FDA-1088 or 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The safety of AIMOVIG has been evaluated in 2,537 patients with migraine who received at least one dose of AIMOVIG, representing 2,310 patient-years of exposure. Of these, 2,057 patients were exposed to 70 mg or 140 mg once monthly for at least 6 months, 1,198 patients were exposed for at least 12 months, and 287 patients were exposed for at least 18 months. In placebo-controlled clinical studies (Studies 1, 2, and 3) of 2,184 patients, 787 patients received at least one dose of AIMOVIG 70 mg once monthly, 507 patients received at least one dose of AIMOVIG 140 mg once monthly, and 890 patients received placebo during 3 months or 6 months of double-blind treatment [see Clinical Studies ( 14 )]. Approximately 84% were female, 91% were white, and the mean age was 42 years at study entry. The most common adverse reactions (incidence ≥ 3% and more often than placebo) in the migraine studies were injection site reactions and constipation. Table 1 summarizes the adverse reactions that occurred during the first 3 months in the migraine studies (Studies 1, 2, and 3). Table 1: Adverse Reactions Occurring with an Incidence of at Least 2% for Either Dose of AIMOVIG and at Least 2% Greater than Placebo During the First 3 Months in Studies 1, 2, and 3 Adverse Reaction AIMOVIG 70 mg Once Monthly N = 787 % AIMOVIG 140 mg Once Monthly N = 507 % Placebo N = 890 % Injection site reactionsa 6 5 3 Constipation 1 3 1 Cramps, muscle spasms < 1 2 < 1 aInjection site reactions include multiple adverse reactions related terms, such as injection site pain and injection site erythema. In Studies 1, 2, and 3, 1.3% of patients treated with AIMOVIG discontinued double-blind treatment because of adverse events. The most frequent injection site reactions were injection site pain, injection site erythema, and injection site pruritus. 6.2 Immunogenicity As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation, including neutralizing antibodies, is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to erenumab-aooe in the studies described below with the incidence of antibodies in other studies or to other products may be misleading. The immunogenicity of AIMOVIG has been evaluated using an immunoassay for the detection of binding anti-erenumab-aooe antibodies. For patients whose sera tested positive in the screening immunoassay, an in vitro biological assay was performed to detect neutralizing antibodies. In controlled studies with AIMOVIG, the incidence of anti-erenumab-aooe antibody development was 6.2% (48/778) in patients receiving AIMOVIG 70 mg once monthly (2 of whom had in vitro neutralizing activity) and 2.6% (13/504) in patients receiving AIMOVIG 140 mg once monthly (none of whom had in vitro neutralizing activity). The neutralizing anti-erenumab-aooe antibody positive rate may be underestimated because of limitations of the assay. Although these data do not demonstrate an impact of anti-erenumab-aooe antibody development on the efficacy or safety of AIMOVIG in these patients, the available data are too limited to make definitive conclusions.